Sarah Farr
Dr. Farr joined Genesys Capital in 2020 as an Associate, bringing to the team eight years of experience at the bench in laboratory research and discovery. She is responsible for sourcing deal flow and carrying out diligence on biotech and medtech investment opportunities. She is also a board observer for Giiant Pharma Inc. and Questat Inc. Past board affiliations include Adapsyn Bioscience, Inc. and EBT Medical, Inc. Dr. Farr currently volunteers on the review committee for the McMaster University Seed Fund.
Before Genesys, Dr. Farr worked as a Business Development Officer in the Industry Partnerships & Commercialization office at the Hospital for Sick Children, where she managed IP, industry partnerships, and start-up opportunities.
Dr. Farr received her PhD from the Faculty of Medicine at the University of Toronto where she studied the effects of glucagon-like peptide-1 (GLP-1) on lipid and lipoprotein metabolism. She also has a Bachelor of Health Science (Honours) with a minor in Biochemistry from McMaster University.
Catalysts for Medical Breakthroughs
At Genesys, relationships come first. With over 25 years experience and our deep subject knowledge, an investment from us is an enduring commitment to the people bringing it to life.
